A gene therapy from Regeneron, a pancreatic cancer medicine from Revolution Medicines and a porphyria drug from Disc Medicine ...

Shares of Praxis Precision Medicines more than tripled Thursday, peaking at $200 apiece, after the company disclosed positive ...

Backed by GV and Arch Venture Partners, Pelage Pharmaceuticals is advancing a first-of-its-kind topical gel designed to ...

However, if pharma manufacturers aren’t using RWD in a strategic way, they’ll miss out on its full potential. And with that, ...

Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that ...

The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called ...

The German biotech banked one of the larger funding rounds this year to support an ovarian and non-small cell lung cancer ...

Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where ...

Study results published in The New England Journal of Medicine show the therapy significantly improved hearing in nearly a ...

Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company ...

The findings position Fabhalta to secure a standard approval in IgA nephropathy — a crowded area of drug research — at a time ...

A deal valuing the Boston biotech’s stock at $700 million hands BioCryst a long-acting injectable for hereditary angioedema ...